Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide

2011 ◽  
Vol 51 (4) ◽  
pp. 586-593 ◽  
Author(s):  
Gezim Lahu ◽  
Nassr Nassr ◽  
Rolf Herzog ◽  
Martin Elmlinger ◽  
Peter Ruth ◽  
...  
Keyword(s):  
1992 ◽  
Vol 71 (4) ◽  
pp. 305-307 ◽  
Author(s):  
Lona L. Christrup ◽  
Jan Bonde ◽  
Søren N. Rasmussen ◽  
Jørn Møller Sonnergaard ◽  
Bodil H. Jensen

1998 ◽  
Vol 14 (5) ◽  
pp. 459-471 ◽  
Author(s):  
UMAR K. MIAN ◽  
MARTIN MAYERS ◽  
YOGENDER GARG ◽  
QING-FENG LIU ◽  
GIRARD NEWCOMER ◽  
...  

1987 ◽  
Vol 33 (12) ◽  
pp. 2225-2229 ◽  
Author(s):  
H F Schran ◽  
T G Rosano ◽  
A E Hassell ◽  
M A Pell

Abstract We measured cyclosporine in whole blood from normal volunteers administered single oral doses of the drug and from two renal-transplant patients on immunosuppressive maintenance therapy, by liquid chromatography (I) and by radioimmunoassay with use of nonspecific polyclonal (II), specific monoclonal (III), and nonspecific monoclonal (IV) antibodies. Concentrations determined by III were equivalent to I, irrespective of cyclosporine dose, concentration, time after dose, or time after transplant. Concentrations determined by II and IV were consistently higher than those by I, owing to cross reactivity with metabolites. Ratios of values by II and IV to those by I increased from less than 1.5 to about 3-4 between 0.5 and 12 h after a single cyclosporine dose, owing to differences in rates of appearance and disappearance of cyclosporine and cross-reacting metabolites, though for the constant 12-h dose intervals in the two renal-transplant patients at steady state these ratios (most within the range 3-4) were relatively stable. Ratios of concentrations measured by IV to those by II (mean of 1.2 for single-dose data, most within the range of 1.2 to 1.5 at steady state) were unaffected by time after dose or time after transplant, suggesting that, despite certain cross-reactivity differences between the two nonspecific antibodies, results are proportional throughout therapy. We therefore propose that III and IV offer alternatives, respectively, to the currently used I and II for cyclosporine monitoring.


2011 ◽  
Vol 26 (S2) ◽  
pp. 929-929 ◽  
Author(s):  
A.S. Höflich ◽  
C. Philippe ◽  
M. Savli ◽  
P. Baldinger ◽  
G.S. Kranz ◽  
...  

IntroductionClinical studies point toward a potential role of the serotonin transporter (SERT) binding as a predictor of clinical outcome in the treatment of depression. After long-term treatment with clinical doses of SSRIs the expected SERT occupancy is about 80%. Here, we were interested to investigate the relationship of SERT occupancy values between short- and longterm treatment.ObjectivesTo test if the SERT occupancy at steady-state can be predicted based on the single dose occupancy by escitalopram (S-citalopram) or citalopram (racemate of S-citalopram and R-citalopram).Methods18 patients with major depressive disorder received either escitalpram (10 mg/d) or citalopram (20 mg/d) in a double-blind, randomized, longitudinal study. They underwent three PET scans using the radioligand [11C]DASB: PET1 baseline, PET2 6 hours after first drug intake and PET3 after three weeks of daily oral treatment. Occupancy of SERT was quantified in six subcortical regions: thalamus, N. caudatus, putamen, mibrain, dorsal raphe and median raphe nuclei. Data was analyzed by means of multiple linear regression models corrected for baseline SERT availability values using SPSS 15.0.ResultsSingle dose occupancy of the SERT significantly predicted steady-state occupancy after three weeks in three regions: thalamus (r2 = 0.45, p = 0.009), N. caudatus (r2 = 0.4, p = 0.006) and putamen (r2 = 0.43, p = 0.005). Other regions did not show significant relationships.ConclusionsIn this study we demonstrated that single-dose occupancy in SERT rich regions such as thalamus, N. caudatus and the putamen could serve as reliable predictors for steady-state occupancy. However, a linear model failed to explain the relationship in regions known for serotonergic cell origin.


1992 ◽  
Vol 43 (6) ◽  
pp. 661-662 ◽  
Author(s):  
P. P. De Deyn ◽  
V. Van de Velde ◽  
W. Verslegers ◽  
J. Saerens ◽  
B. A. Pickut ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document